强韧的事物不太在意环境。—-塔勒布 一番调研之后,我今天把这只拥有理想风险收益比的的专业疫苗公司介绍给诸位虎友。 源自discord的一篇深度分析文章认为,因其独家疫苗、记录、及上帝也称扬的合作伙伴(辉瑞),VALN将是下一个吉利德。 VALN is the Next GILD For its ExclusiveVaccines,Record,God-Glorifying Partners... 文章最后结论: 辉瑞可以让莱姆病疫苗的收入与默克的HPV疫苗收入(100亿美元)持平,并最终为VALN获得20亿美元的特许权收入,不考虑投资组合的其他部分,这大约是200亿美元的市值或目前价格的25倍。 And down the road in Lyme I think it is reasonable that with Pfizer's long arm they canmake Lyme equal HPV, and eventually get $2B in royalties for Valneva. That's about a$20B market cap or 25X from here, without the rest of the portfolio. 我抽时间为读者们提供细节分析。